Therefore, we hypothesized that CYP1B1 and MAP1B are therapeutic targets of these two drugs, while ABL2 is a target of BC cell resistance to doxorubicin; moreover, the underlying mechanism needs further exploration. The gene discussed is CYP1B1; the disease is breast cancer.